BiotechTube
MedRegen

MedRegen

Baltimore, United States· Est.
medregenco.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $6.7M

Overview

MedRegen is a private, clinical-stage biotech focused on regenerative medicine via a novel small molecule, MRG-001. The company's platform leverages endogenous bone marrow stem cells, mobilizing them to sites of injury to promote repair and modulate inflammation. Its lead asset is in Phase II trials for Acute Respiratory Distress Syndrome (ARDS) and wound healing, with a preclinical candidate, MRG-002, in development. The company operates with private investment and has established key partnerships for manufacturing and clinical execution.

Acute Respiratory Distress Syndrome (ARDS)Wound HealingOrgan InjuryLiver Diseases

Technology Platform

Small molecule platform (MRG-001) designed to mobilize endogenous bone marrow-derived stem cells and immunomodulatory cells to sites of tissue injury to promote regeneration and suppress inflammation.

Funding History

2
Total raised:$6.7M
Seed$5.5M
Grant$1.2M

Opportunities

MRG-001 addresses large unmet needs in critical care (ARDS) and chronic wound management, with no approved pharmacologic therapies for ARDS.
The platform's broad applicability to tissue injury presents a pipeline-in-a-product opportunity across multiple organ systems.
Successful Phase II data could attract strategic partnerships or acquisition interest from larger pharma companies.

Risk Factors

High clinical risk as Phase II trials must confirm efficacy of a novel mechanism in complex human diseases.
Significant financing risk as a private, pre-revenue company needing capital for expanded trials.
Competitive and regulatory risks are inherent in developing first-in-class therapies for challenging indications.

Competitive Landscape

Competition in regenerative medicine includes cell-based therapies, growth factors, and other immunomodulators. In ARDS, MedRegen competes against supportive care and investigational agents targeting inflammation. Its drug-based stem cell mobilization approach is distinctive but may face competition from other mobilizing agents or direct cell infusion therapies in development.

More companies in United States →